Journal Article Page
European UrologyVolume 63, issue 5, pages e59-e66, May 2013
Reply from Author re: Maurizio Brausi, Salvatore Siracusano. Collateral Activity of Immunotherapy with Bacillus Calmette-Guérin for the Treatment of Non–muscle-invasive Transitional Cell Carcinoma of the Bladder: New Insights. Eur Urol 2013;63:836–7
Published online 3 December 2012, pages 837 - 838
Refers to article:
Intravesical Bacille Calmette-Gurin Eradicates Bacteriuria in Antibiotic-nave Bladder Cancer Patients
Accepted 12 August 2012
May 2013 (Vol. 63, Issue 5, pages 832 - 835)
Refers to article:
Collateral Activity of Immunotherapy with Bacillus Calmette-Gurin for the Treatment of Nonmuscle-invasive Transitional Cell Carcinoma of the Bladder: New Insights
May 2013 (Vol. 63, Issue 5, pages 836 - 837)
Intravesical bacillus Calmette-Guérin (BCG) induces a cascade of robust immunologic responses in the bladder that conspire to destroy urothelial carcinoma. Although unproven, the same augmented innate and activated immune reactions, as Brausi and Siracusano point out , may explain how BCG might also eradicate uropathogens entrenched within the mucosa.
BCG therapy has been shown to be safe and effective in antibiotic-naïve bacteriuric bladder cancer patients . I agree that further studies are necessary to corroborate these findings, especially the collateral damage BCG may cause to chronic bacteriuria . For that to happen, however, urologists must be willing to treat infected patients with BCG and monitor them closely without resorting to frequent use of antibiotics to sterilize the urine. Because of guidelines and traditional practices warning against outpatient urologic procedures in patients with positive urine cultures, that becomes difficult. So far and despite my best efforts, I have been unable to persuade co-investigators at other institutions to participate in such studies, although I am open and happy to share our data and protocols as well as to collaborate in multicenter trials.
Conflicts of interest
The author has nothing to disclose.
-  M. Brausi, S. Siracusano. Collateral activity of immunotherapy with bacillus Calmette-Guérin for the treatment of non–muscle-invasive transitional cell carcinoma of the bladder: new insights. Eur Urol. 2013;63:836-837 Abstract, Full-text, PDF, Crossref.
-  H.W. Herr. Intravesical BCG in bladder cancer patients with asymptomatic bacteriuria. JAMA. 2011;305:1413-1414 Crossref.
-  H.W. Herr. Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients. Eur Urol. 2013;63:832-835 Abstract, Full-text, PDF, Crossref.
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
© 2012 Published by Elsevier B.V.
Recommend this article
Currently this article has a rating of 0. Please log in to recommend it.